Compare Stocks → The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ENTXNASDAQ:LIFENASDAQ:NTGNNASDAQ:OTLKNASDAQ:VICL Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTXEntera Bio$1.98-11.6%$1.56$0.52▼$3.35$57.02M1.7211,814 shs247,995 shsLIFEaTyr Pharma$1.60-1.2%$1.85$1.08▼$2.70$108.71M1.25513,729 shs92,892 shsNTGNNeon Therapeutics$3.07$3.03$0.88▼$6.25$88.93M-0.81516,108 shsN/AOTLKOutlook Therapeutics$8.16-1.6%$8.61$4.00▼$40.60$106.16M0.04544,931 shs118,176 shsVICLVical$1.24$0.60▼$1.47$21.01M0.321.44 million shs35,024 shs7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTXEntera Bio+0.90%-15.79%+58.84%+129.72%+157.47%LIFEaTyr Pharma+1.89%-7.95%-19.00%+8.00%-13.37%NTGNNeon Therapeutics0.00%0.00%0.00%0.00%0.00%OTLKOutlook Therapeutics-3.72%-8.30%+11.95%+18.77%-63.96%VICLVical0.00%0.00%0.00%0.00%+44.90%Biden’s $374B Giveaway Into This Sector (Ad)Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right hereClick here for the full storyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTXEntera Bio1.7449 of 5 stars3.53.00.00.03.90.00.0LIFEaTyr Pharma1.9471 of 5 stars3.43.00.00.03.21.70.0NTGNNeon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOTLKOutlook Therapeutics2.9895 of 5 stars4.42.00.00.02.91.70.6VICLVicalN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTXEntera Bio3.00Buy$10.00405.05% UpsideLIFEaTyr Pharma2.75Moderate Buy$23.671,379.17% UpsideNTGNNeon TherapeuticsN/AN/AN/AN/AOTLKOutlook Therapeutics2.88Moderate Buy$46.43468.93% UpsideVICLVicalN/AN/AN/AN/ACurrent Analyst RatingsLatest OTLK, ENTX, LIFE, NTGN, and VICL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2024ENTXEntera BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.003/27/2024OTLKOutlook TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$50.003/25/2024OTLKOutlook TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$30.003/15/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.003/15/2024LIFEaTyr PharmaRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$19.00 ➝ $16.002/21/2024LIFEaTyr PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$35.002/16/2024OTLKOutlook TherapeuticsCapital One FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight2/15/2024OTLKOutlook TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$60.001/25/2024OTLKOutlook TherapeuticsBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$31.401/25/2024OTLKOutlook TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$40.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTXEntera Bio$130K438.65N/AN/A$0.36 per share5.50LIFEaTyr Pharma$353K307.95N/AN/A$1.54 per share1.04NTGNNeon TherapeuticsN/AN/AN/AN/A$0.50 per shareN/AOTLKOutlook TherapeuticsN/AN/AN/AN/A($1.11) per shareN/AVICLVical$1.62M0.00N/AN/A$1.82 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTXEntera Bio-$8.89M-$0.31N/AN/AN/AN/A-101.78%-83.90%5/3/2024 (Estimated)LIFEaTyr Pharma-$50.39M-$0.96N/AN/AN/AN/A-49.84%-39.12%5/14/2024 (Estimated)NTGNNeon Therapeutics-$79.78M-$2.86N/AN/AN/AN/A-199.09%-137.14%N/AOTLKOutlook Therapeutics-$58.98M-$4.00N/AN/AN/AN/A-3,741.39%-132.37%5/20/2024 (Estimated)VICLVical-$16.25M-$0.81N/AN/AN/A-1,002.10%-29.46%-27.85%N/ALatest OTLK, ENTX, LIFE, NTGN, and VICL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/14/2024Q4 2023LIFEaTyr Pharma-$0.23-$0.25-$0.02-$0.25N/AN/A3/8/2024Q4 2023ENTXEntera Bio-$0.08-$0.07+$0.01-$0.07N/AN/A2/14/2024Q1 2024OTLKOutlook Therapeutics-$1.00-$0.80+$0.20-$0.04N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTXEntera BioN/AN/AN/AN/AN/ALIFEaTyr PharmaN/AN/AN/AN/AN/ANTGNNeon TherapeuticsN/AN/AN/AN/AN/AOTLKOutlook TherapeuticsN/AN/AN/AN/AN/AVICLVicalN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTXEntera BioN/A10.3210.32LIFEaTyr Pharma0.026.276.27NTGNNeon Therapeutics0.431.583.00OTLKOutlook TherapeuticsN/A0.440.44VICLVicalN/A36.8436.84OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTXEntera Bio14.11%LIFEaTyr Pharma61.72%NTGNNeon Therapeutics54.71%OTLKOutlook Therapeutics11.20%VICLVical29.06%Insider OwnershipCompanyInsider OwnershipENTXEntera Bio8.90%LIFEaTyr Pharma3.70%NTGNNeon Therapeutics38.93%OTLKOutlook Therapeutics5.30%VICLVical4.58%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableENTXEntera Bio1728.80 million26.24 millionOptionableLIFEaTyr Pharma5667.94 million65.43 millionOptionableNTGNNeon Therapeutics10228.97 millionN/ANot OptionableOTLKOutlook Therapeutics2413.01 million12.32 millionOptionableVICLVical3022.84 millionN/ANot OptionableOTLK, ENTX, LIFE, NTGN, and VICL HeadlinesSourceHeadlineEvan Gershkovich’s sister was the quiet one. Now she’s his voice.msn.com - March 29 at 9:52 AMVideo: Travis Kelce’s Friends Attempt to Distract Him in Golf by Playing Taylor Swift’s Songijr.com - March 29 at 9:52 AMSong Suffragettes celebrates 10 years with Wynonna, female country chart-toppers, moremsn.com - March 29 at 9:52 AMSong lyrics getting simpler, more repetitive, angry and self-obsessed – studytheguardian.com - March 29 at 9:52 AMBeyoncé’s Younger Daughter Rumi Carter Joins Her on New Song ‘Protector’msn.com - March 29 at 2:11 AMBeyoncé features Shaboozey on her song 'Spaghettii': Who is the hip-hop, country artist?msn.com - March 29 at 2:11 AMCreed frontman Scott Stapp on singing his 'life story,' moving to Nashville and finding a dream teammsn.com - March 28 at 9:10 PMBBC stands by replacing singer with AI-generated voicemsn.com - March 28 at 9:10 PMSong Lyrics Really Are Getting Simpler and More Repetitive, Study Findsscientificamerican.com - March 28 at 9:10 PMFunniest misheard Beyoncé lyrics, from 'Singing lettuce' to 'No bottom knee'msn.com - March 28 at 9:10 PMKanye wife Bianca Censori’s voice heard for first time in newly resurfaced videonydailynews.com - March 28 at 4:10 PMTop 'American Idol' and 'The Voice' contestants come from these states: Where Tennessee ranks in the listtennessean.com - March 28 at 4:10 PMSong Lyrics Are Now More Repetitive and Simple, Study Confirmsmsn.com - March 28 at 4:10 PMKJP Declares Press Gaggle off the Record as Obama’s Voice Is Heardijr.com - March 28 at 4:10 PMSong lyrics have become angrier since the 80s, study showsmsn.com - March 28 at 4:10 PMBoston Red Sox minor league pitcher, former Navy standout Noah Song set to undergo Tommy John surgerybaltimoresun.com - March 28 at 4:10 PMBachelor Joey Graziadei Reveals the Taylor Swift Song That Reminds Him of New Fiancée Kelsey Andersonmsn.com - March 28 at 4:10 PMSong Lyrics Are Getting Simpler, More Repetitive: Studybarrons.com - March 28 at 4:10 PM‘Past Lives’ director Celine Song delivers Pan Asian American Heritage Month keynote speechyaledailynews.com - March 28 at 11:10 AMVampire Weekend Share Video for New Song “Mary Boone”: Watchyahoo.com - March 28 at 11:10 AMFans freak hearing Kanye West’s wife Bianca Censori’s voice for first time in old videomsn.com - March 28 at 11:10 AMBeyoncé's ‘Cowboy Carter’ tracklist is a puzzle. What we've deciphered so farmsn.com - March 28 at 11:10 AMKate Hudson celebrates motherhood in new song 'Live Forever'upi.com - March 28 at 11:10 AMThis song is our storyfoxnews.com - March 28 at 11:10 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop Headlines3 Value Stocks Too Small For Buffett’s PortfolioMarch 28, 2024 12:16 PMView 3 Value Stocks Too Small For Buffett’s PortfolioFoot Locker Builds Up Another Head of Steam; Gains ImminentMarch 28, 2024 10:58 AMView Foot Locker Builds Up Another Head of Steam; Gains Imminent5 Stocks in the Current Bull Market with Upside to ComeApril 5, 2024 10:14 AMView 5 Stocks in the Current Bull Market with Upside to Come5 Top-Rated Dividend Stocks With Double-Digit UpsideMarch 25, 2024 11:19 AMView 5 Top-Rated Dividend Stocks With Double-Digit UpsideBlackstone’s $10 Billion Bet on Property Prices Going UpApril 11, 2024 7:30 AMView Blackstone’s $10 Billion Bet on Property Prices Going UpAll Headlines Company DescriptionsEntera BioNASDAQ:ENTXEntera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and hGh for the GH deficiency. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.aTyr PharmaNASDAQ:LIFEaTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.Neon TherapeuticsNASDAQ:NTGNNeon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Outlook TherapeuticsNASDAQ:OTLKOutlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.VicalNASDAQ:VICLVical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.